Quantcast
Connect with us

What is the ACE2 receptor, how is it connected to coronavirus and why might it be key to treating COVID-19? The experts explain

Published

on

Scientists around the world are racing to find vaccines and treatments for the new coronavirus, which has become a raging pandemic Handout National Institutes of Health:AFP:File

In the search for treatments for COVID-19, many researchers are focusing their attention on a specific protein that allows the virus to infect human cells. Called the angiotensin-converting enzyme 2, or ACE2 “receptor,” the protein provides the entry point for the coronavirus to hook into and infect a wide range of human cells. Might this be central in how to treat this disease?

ADVERTISEMENT

We are scientists with expertise in pharmacology, molecular biology and biochemistry, with a strong commitment to applying these skills to the discovery of novel therapies for human disease. In particular, all three authors have experience studying angiotensin signaling in various disease settings, a biochemical pathway that appears to be central in COVID-19. Here are some of the key issues to understand about why there’s so much focus on this protein.

What is the ACE2 receptor?

ACE2 acts as the receptor for the SARS-CoV-2 virus and allows it to infect the cell.
The Conversation, CC BY-SA

ACE2 is a protein on the surface of many cell types. It is an enzyme that generates small proteins – by cutting up the larger protein angiotensinogen – that then go on to regulate functions in the cell.

Using the spike-like protein on its surface, the SARS-CoV-2 virus binds to ACE2 – like a key being inserted into a lock – prior to entry and infection of cells. Hence, ACE2 acts as a cellular doorway – a receptor – for the virus that causes COVID-19.

Where in the body is it found?

ACE2 is present in many cell types and tissues including the lungs, heart, blood vessels, kidneys, liver and gastrointestinal tract. It is present in epithelial cells, which line certain tissues and create protective barriers.

The exchange of oxygen and carbon dioxide between the lungs and blood vessels occurs across this epithelial lining in the lung. ACE2 is present in epithelium in the nose, mouth and lungs. In the lungs, ACE2 is highly abundant on type 2 pneumocytes, an important cell type present in chambers within the lung called alveoli, where oxygen is absorbed and waste carbon dioxide is released.

ADVERTISEMENT

What is the normal role ACE2 plays in the body?

The ACE enzyme converts angiotensin I into angiotensin II. The main role of ACE2 is to break down angiotensin II into molecules that counteract angiotensin II’s harmful effects; but if the virus occupies the ACE2 ‘receptor’ on the surface of cells, then its role is blunted (red lines). Drugs called ACE inhibitors inhibit the formation of angiotensin II, which would otherwise interact with the angiotensin type 1 receptor to produce tissue damage and inflammation. Drugs called ARBs block angiotensin II from interacting with its receptor. Figure adapted from NEJM
The Conversation, CC BY-SA

ACE2 is a vital element in a biochemical pathway that is critical to regulating processes such as blood pressure, wound healing and inflammation, called the renin-angiotensin-aldosterone system (RAAS) pathway.

ACE2 helps modulate the many activities of a protein called angiotensin II (ANG II) that increases blood pressure and inflammation, increasing damage to blood vessel linings and various types of tissue injury. ACE2 converts ANG II to other molecules that counteract the effects of ANG II.

Of greatest relevance to COVID-19, ANG II can increase inflammation and the death of cells in the alveoli which are critical for bringing oxygen into the body; these harmful effects of ANG II are reduced by ACE2.

ADVERTISEMENT

When the SARS-CoV-2 virus binds to ACE2, it prevents ACE2 from performing its normal function to regulate ANG II signaling. Thus, ACE2 action is “inhibited,” removing the brakes from ANG II signaling and making more ANG II available to injure tissues. This “decreased braking” likely contributes to injury, especially to the lungs and heart, in COVID-19 patients.

Does everyone have the same number of ACE2 on their cells?

No. ACE2 is present in all people but the quantity can vary among individuals and in different tissues and cells. Some evidence suggests that ACE2 may be higher in patients with hypertension, diabetes and coronary heart disease. Studies have found that a lack of ACE2 (in mice) is associated with severe tissue injury in the heart, lungs and other tissue types.

ADVERTISEMENT

Does the quantity of receptors determine whether someone gets more or less sick?

This is unclear. The SARS-CoV-2 virus requires ACE2 to infect cells but the precise relationship between ACE2 levels, viral infectivity and severity of infection are not well understood.

Even so, aside from its ability to bind the SARS-CoV-2 virus, ACE2 has protective effects against tissue injury, by mitigating the pathological effects of ANG II.

When the amount of ACE2 is reduced because the virus is occupying the receptor, individuals may be more susceptible to severe illness from COVID-19. That is because enough ACE2 is available to facilitate viral entry but the decrease in available ACE2 contributes to more ANG II-mediated injury. In particular, reducing ACE2 will increase susceptibility to inflammation, cell death and organ failure, especially in the heart and the lung.

ADVERTISEMENT

Which organs are most severely damaged by SARS-CoV-2?

The lungs are the primary site of injury by SARS-CoV-2 infection, which causes COVID-19. The virus reaches the lungs after entry in the nose or mouth.

ANG II drives lung injury. If there is a decrease in ACE2 activity (because the virus is binding to it), then ACE2 can’t break down the ANG II protein, which means there is more of it to cause inflammation and damage in the body.

The virus also impacts other tissues that express ACE2, including the heart, where damage and inflammation (myocarditis) can occur. The kidneys, liver and digestive tract can also be injured. Blood vessels may also be a site for damage.

In a recent research paper, we argued that a key factor that determines severity of damage in patients with COVID-19 is abnormally high ANG II activity.

ADVERTISEMENT

What are ACE inhibitors? Are they a possible treatment or prophylactic for SARS-CoV-2?

Angiotensin converting enzyme (ACE, aka ACE1) is another protein, also found in tissues such as the lung and heart, where ACE2 is present. Drugs that inhibit the actions of ACE1 are called ACE inhibitors. Examples of these drugs are ramipril, lisinopril, and enalapril. These drugs block the actions of ACE1 but not ACE2. ACE1 drives the production of ANG II. In effect, ACE1 and ACE2 have a “yin-yang” relationship; ACE1 increases the amount of ANG II, whereas ACE2 reduces ANG II.

By inhibiting ACE1, ACE inhibitors reduce the levels of ANG II and its ability to increase blood pressure and tissue injury. ACE inhibitors are commonly prescribed for patients with hypertension, heart failure and kidney disease.

Another commonly prescribed class of drugs, angiotensin receptor blockers (ARBs, e.g., losartan, valsartan, etc.) have similar effects to ACE inhibitors and may also be useful in treating COVID-19.

Evidence for a protective effect of ACE inhibitors and angiotensin receptor blockers in patients with COVID-19 was shown in recent work co-authored by one of us – Dr. Loomba.

ADVERTISEMENT

No evidence exists to suggest prophylactic use of these drugs; we do not advise readers to take these drugs in the hopes that they will prevent COVID-19. We wish to emphasize that patients should only take these drugs as instructed by their health care provider.

New clinical trial tests ACE inhibitor against SARS-CoV-2

In collaboration with a multidisciplinary group of investigators, Dr. Loomba has initiated a multicenter (randomized, double-blinded, placebo-controlled) clinical trial to examine the efficacy of ramipril – an ACE inhibitor – compared to a placebo in reducing mortality, ICU admission or need for mechanical ventilation in patients with COVID-19.

[Get facts about coronavirus and the latest research. Sign up for The Conversation’s newsletter.]The Conversation

Krishna Sriram, Postdoctoral Fellow, University of California San Diego; Paul Insel, Professor of Pharmacology and Medicine, University of California San Diego, and Rohit Loomba, Professor of Medicine, University of California San Diego

This article is republished from The Conversation under a Creative Commons license. Read the original article.


Report typos and corrections to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

2020 Election

‘Very good news’: Law prof praises Kentucky’s bipartisan compromise to allow everyone to vote by mail

Published

on

The state of Kentucky was praised on Friday after a bipartisan agreement was reached to expand voting by mail during the COVID-19 pandemic.

"Any Kentucky voter wary of the risk of COVID-19 will be able to vote in the Nov. 3 general election by mailing in an absentee ballot. Voters will also have the option of casting a ballot in person during the three weeks leading up to the election, or waiting until Election Day," the Lexington Herald-Leader reported Friday.

Continue Reading

Breaking Banner

Trump supporter shut down on Fox News: ‘Turns out Stephen Moore is not a very good epidemiologist’

Published

on

University of Michigan economics professor Justin Wolfers mocked Trump 2016 economics advisor Stephen Moore on Fox News over the administrations bungled response to the COVID-19 pandemic.

"Let's not have economists play epidemiologists here, mate," Wolfers said in his Australian accent.

"We actually tried Steve's prescription, which was not shutting down, that's what the sunbelt states did," he explained.

"What have you got? You've got spreading disease everywhere and you've got the economies there forced to shut down," he explained.

"We tried what Stephen Moore wanted -- it turns out Stephen Moore is not a very good epidemiologist," Wolfers concluded.

Continue Reading
 

COVID-19

COVID-19 is killing over twice as many Black Americans as whites, new report says

Published

on

PHILADELPHIA — Black individuals are nearly three times as likely to contract COVID-19 and twice as likely to die from the virus, compared to white individuals, according to a new report by the National Urban League. Researchers have struggled to measure with precision the race gaps in COVID-19 because much of the early data reported by hospitals did not include information about patients’ race — as of early August, Pennsylvania has reported race data for about half of its cases. But the National Urban League’s State of Black America report adds to a growing body of research that has found the ... (more…)

Continue Reading
 
 
You need honest news coverage. Help us deliver it. Join Raw Story Investigates for $1. Go ad-free.
close-image